case_images: PMC9314645_01
case_images: Levels of HBV DNA during CD7 CAR-T therapy bridging to HSCT.
case_images: fimmu-13-931452-g001.jpg
case_images: PMC9314645_01_fimmu-13-931452-g001.jpg
case_images: f1
case_images: The changes in HBV DNA during treatment are illustrated in  Figure 1 .
case_images: PCR was used to monitor the change trend of CD7 CAR T-cell count in vivo during CAR-T and transplantation.
case_images: fimmu-13-931452-g002.jpg
case_images: PMC9314645_01_fimmu-13-931452-g002.jpg
case_images: f2
case_images: Figure 2 ). Four and a half months after transplantation, abnormal T lymphocytes expressing CD7-CD5+ were detected by flow cytometry, but the patient was still in complete remission with full donor chimerism in both bone marrow and CD3+ cells in peripheral blood.
case_images: MRD was detected by flow cytometry during CD7 CAR-T therapy bridging to HSCT.
case_images: fimmu-13-931452-g003.jpg
case_images: PMC9314645_01_fimmu-13-931452-g003.jpg
case_images: f3
case_images: Half a month after reducing immunosuppressive agents, the flow cytometry of bone marrow turned negative ( Figure 3 ).
case_images: Sequential infusion of anti-CD7 CAR-T therapy bridging to HSCT. (A) Levels of WBC and PLT during CAR-T therapy bridging to HSCT. (B) Levels of ALS and AST during CAR-T therapy bridging to HSCT. (C) Levels of TBIL and DBIL during CAR-T therapy bridging to HSCT. (D) Levels of IL-6, TNF-a, IL-10 and CD25 during CAR-T therapy bridging to HSCT.
case_images: fimmu-13-931452-g004.jpg
case_images: PMC9314645_01_fimmu-13-931452-g004.jpg
case_images: f4
case_images: Blood indicators (white blood cells, platelets), biochemical indicators (AST, ALT, DBIL, TBIL), and cytokines (interleukin 6, tumor necrosis factor alpha, interleukin 10, soluble CD25, interferon gamma) were all monitored ( Figure 4 ). Engrafted leukocytes survived 18 days after transplantation ( Figure 4A ). TBIL and DBIL in  Figure 4C ). There was a transient increase in transaminase and bilirubin after transplantation. The concentrations of cytokines (interleukin 6, tumor necrosis factor alpha, interleukin 10, soluble CD25, interferon gamma) peaked four days after CD7 CAR-T treatment, consistent with the CRS response, then increased to another peak after HSCT, and fell after that ( Figure 4D ).